Emcure Pharmaceuticals - MFs raise stake for 3 straight quarters in 5 mid-cap stocks; shares gain up to 75% YTD
NiveshIQ
NSE: EMCURE · Healthcare
Emcure Pharmaceuticals Ltd.
₹1,883.50▲ ₹11.70 (+0.63%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on EMCURE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Limited, founded in 1981 and headquartered in Pune, India, is a diversified pharmaceutical company offering a broad portfolio across therapeutic areas such as oncology, anti-infectives, cardiovascular, and metabolic disorders. The company’s revenue in FY27 stood at ₹9,683 crore with a net income of ₹1,011 crore, reflecting steady profitability driven by high-margin specialty drugs and a growing presence in the Indian market. Recent corporate actions include the consolidation of its wholly-owned subsidiaries, merging arms Zuventus and Emcutix, to streamline operations and reduce overheads. Emcure has a strategic partnership with Novo Nordisk India for the development and commercialization of Poviztra, a semaglutide injection for weight loss, positioning it in the high
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,658 Cr +11.20% | ₹7,896 Cr +18.60% | ₹9,204 Cr +16.56% |
| EBITDA Margin | 18.47% | 18.67% | 20.26% |
| Net Profit | ₹528.00 Cr -6.00% | ₹681.33 Cr +34.10% | ₹924.36 Cr +35.67% |
| EPS | ₹27.53 | ₹36.43 | ₹48.77 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Emcure Pharma - Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a look
Emcure Pharma - Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a look
🔒
+ 3 more stories about Emcure Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 580 Cr, PAT ₹294 Cr, EPS ₹15.50, EBITDA margin 20.6%. Growth context: revenue YoY +22.8%, PAT YoY +42.1%, revenue QoQ +4.5%, PAT QoQ +20.8%. Street verdict: strong beat, revenue surprise +7.8%, PAT surprise +22.4%.
Management commentary points to product launches, approvals, and therapy-mix improvement and order wins, deal pipeline, ...
FY26 (last completed FY): revenue ₹9, 204 Cr, PAT ₹924 Cr, EBITDA margin 20.3%, EPS ₹48.77. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for EMCURE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track EMCURE alongside your other holdings
Unlock full EMCURE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Emcure Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Emcure Pharmaceuticals Ltd. (EMCURE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Emcure Pharmaceuticals Ltd.?
Emcure Pharmaceuticals Ltd. operates in the Healthcare sector with a market capitalisation of ₹3,716,620.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.